第55届美国血液学会年会骨髓增生异常综合征研究领域新进展：5-氮杂胞苷和地西他滨疗效及治疗方案评述

介绍第55届美国血液学会（ASH）年会有关骨髓增生异常综合征（MDS）研究领域对5-氮杂胞苷和地西他滨的评价和展望.除了较年长的女性患者,自2004年5-氮杂胞苷问世以来,MDS患者的生存期未有明显延长.但是,临床和试验数据提示,随着5-氮杂胞苷和地西他滨应用的不断扩展,会对MDS产生明显的影响.而且,这些药物是相对于传统细胞毒性药物的成功范例,其为进一步开展这方面的研究提供了新的思维和方法.

New progress of myelodysplastic syndromes in the 55th ASH annual meeting

New progress of myelodysplastic syndomes (MDS) in the 55th ASH annual meeting on 5-azacytidine and decitabine was reviewed. Except in older females, the survival time for a diagnosis of MDS in the United States does not seem to have substantially improved since the introduction of 5-azacytidine into the market in 2004. However, clinical and mechanism data suggest that judicious, mechanism-based application and optimization of these agents will have increasingly meaningful impact. Moreover, these drugs are exemplars of an inspiring alternative to the traditional cytotoxic paradigm and should pave the way for additional relatively nontoxic but broadly effective agents.